# Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function

> **NCT03442725** · PHASE1 · COMPLETED · sponsor: **Ipsen** · enrollment: 16 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Telotristat etiprate

## Key facts

- **NCT ID:** NCT03442725
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-09
- **Primary completion:** 2018-04-27
- **Final completion:** 2018-05-13
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03442725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03442725, "Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03442725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*